Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $74.8333.

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Vera Therapeutics in a research note on Friday, November 28th. Wedbush increased their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Pivotal Research set a $73.00 target price on Vera Therapeutics in a research report on Friday, December 5th. Finally, Bank of America upped their target price on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th.

Insider Activity

In other Vera Therapeutics news, Director Patrick G. Enright purchased 5,882 shares of Vera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the acquisition, the director owned 5,882 shares in the company, valued at $249,985. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 15,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total transaction of $435,900.00. Following the transaction, the senior vice president owned 47,839 shares in the company, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 16.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares during the last quarter. Quantbot Technologies LP purchased a new position in Vera Therapeutics in the second quarter valued at about $51,000. Virtus Investment Advisers LLC raised its holdings in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after buying an additional 2,757 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Vera Therapeutics by 13.3% during the second quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after buying an additional 615 shares during the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $43.26 on Friday. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. The stock’s fifty day moving average is $45.88 and its two-hundred day moving average is $32.54. Vera Therapeutics has a 52 week low of $18.53 and a 52 week high of $56.05. The company has a market capitalization of $2.77 billion, a PE ratio of -10.84 and a beta of 1.16.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter in the previous year, the firm earned ($0.85) EPS. As a group, analysts expect that Vera Therapeutics will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.